Belatacept dosing in Lung Transplantation: is there a Method to the Madness?

Christine Pham, Brett J. Pierce, Simon W. Yau, Georges J. Youssef, Ahmad Goodarzi, Howard J. Huang

Research output: Contribution to journalArticlepeer-review

Abstract

Data supporting the use of belatacept in non-abdominal organs are limited to case series and small cohorts involving patients requiring conversion due to CNI intolerance or contraindication. Review articles summarizing the efficacy of belatacept salvage therapy in lung transplantation have previously been published, however, dosing regimens are highly variable and uniform guidance is lacking. In this article, indications and considerations for belatacept use in lung transplant recipients are reviewed with a specific focus on dosing regimens. Utilization of standardized dosing protocols to guide belatacept conversion will both improve the ability to directly assess outcomes and provide the opportunity to improve future patient care. A suggested framework for dosing selection and timeline for cross titration is proposed herein.

Original languageEnglish (US)
JournalOBM Transplantation
Volume5
Issue number3
DOIs
StatePublished - 2021

Keywords

  • Lung transplantation
  • belatacept
  • dosing
  • immunosuppression

ASJC Scopus subject areas

  • Biochemistry, medical
  • Surgery
  • Transplantation
  • Immunology

Fingerprint

Dive into the research topics of 'Belatacept dosing in Lung Transplantation: is there a Method to the Madness?'. Together they form a unique fingerprint.

Cite this